BRCA2 and ovarian serous adenocarcinoma: In a cohort of 53 patients with serous ovarian cancer (29 BRCA1-mutated, 8 BRCA2-mutated, 16 HR-proficient), BRCA-mutated tumors exhibited increased CD3+ and CD8+ T cells as compared to HR-proficient tumors.